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Delayed cerebral ischemia (DCI) is a feared and significant medical complication follow-
ing aneurysmal subarachnoid hemorrhage (aSAH). It occurs in about 30% of patients
surviving the initial hemorrhage, mostly between days 4 and 10 after aSAH. Clinical deteri-
oration attributable to DCI is a diagnosis of exclusion and especially difficult to diagnose in
patients who are comatose or sedated.The latter are typically patients with a high grade on
the World Federation of Neurosurgical Societies scale (WFNS grade 4–5), who represent
approximately 40–70% of the patient population with ruptured aneurysms. In this group
of patients, the incidence of DCI is often underestimated and higher when compared to
low WFNS grade patients. To overcome difficulties in diagnosing DCI, which is especially
relevant in sedated and comatose patients, the article reports the most recent recom-
mendation for definition of DCI and discusses their advantages and problematic issues in
neurocritical care practice. Finally, appropriate neuromonitoring techniques and their clinical
impact in high-grade SAH patients are summarized.
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INTRODUCTION: THE PROBLEM – DELAYED CEREBRAL
ISCHEMIA
Delayed cerebral ischemia (DCI) is a feared and significant medical
complication following aneurysmal subarachnoid hemorrhage
(aSAH). It occurs in about 30% of patients surviving the ini-
tial hemorrhage, mostly between days 4 and 10 after aSAH. The
known clinical symptoms such as decrease in the level of con-
sciousness and focal signs such as aphasia and hemiparesis may
be reversible or otherwise progress to cerebral infarction resulting
in an unfavorable outcome or even death (1). Clinical deterio-
ration attributable to DCI is a diagnosis after exclusion of other
causes (such as infection, hypotension, hyponatremia, and oth-
ers), and it is especially difficult to diagnose in patients who are
comatose or sedated (1, 2). The latter are typically patients with
a high grade on the World Federation of Neurosurgical Societies
scale (3) (WFNS grade 4–5), which represent approximately 40–
70% of the patient population with ruptured aneurysms. In this
group of patients, the incidence of DCI is often underestimated
(4) and higher when compared to low WFNS grade patients (5).
As shown by Rabinstein and colleagues, as independent predictive
factors of a very low risk to develop DCI at age 68 years or older,
WFNS I–III at presentation and a modified Fisher grade 1–2 were
identified, with specificity of 100% and positive predictive value
of 100% (5). As mortality for high-grade patients remains high,
efforts have been made to improve diagnosis and treatment of
DCI-related damage and to identify a patient subgroup who can
expect a better outcome (6).
DCI AND ANGIOGRAPHIC VASOSPASM
Angiographic vasospasm can be associated with reductions
in cerebral perfusion measured with 15O-positron emission
tomographic imaging (7). However, regional hypoperfusion and
oligemia frequently occurred in territories and patients with no
angiographic vasospasm. Furthermore, the development of arter-
ial spasm as diagnosed by angiography or transcranial Doppler
(TCD) had no consistent relationship with 3-month outcome
(8). Other factors in addition to large-vessel narrowing must
contribute to critical reductions in perfusion. So far, because of
the common association between clinical deterioration from DCI
and angiographic vasospasm, arterial narrowing on angiography
and increased blood flow velocities on TCD ultrasound exam-
ination are often used as surrogate diagnostic tool (2). This,
however, is problematic as the old paradigm of “clinical dete-
rioration due to DCI is equivalent to angiographic vasospasm”
has changed in the last years (9). One of the landmarks was the
clazosentan-study results (conscious-2), an endothelin-receptor
antagonist that effectively resolves angiographic vasospasm, but
failed to reduce mortality, DCI-related morbidity, or functional
outcome in relation to aSAH (10). Patients with aSAH may
have clinical deterioration attributable to DCI in the absence
of radiologically confirmed vasospasm (11, 12). This may be
the case because angiography is not obtained at the moment
of clinical deterioration or because DCI is caused by other
factors (2).
DCI AND INFARCTION – DEFINITIONS
Throughout the literature, various means of defining vasospasm
are used. To overcome difficulties to diagnose DCI, which is espe-
cially relevant in sedated and comatose patients, an excellent sum-
mary of possible definitions and their clinical impact, evaluated in
580 aSAH patients, was performed by Frontera and colleagues (8).
More recently, to improve comparability of future SAH studies,
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two different definitions were reformulated by a multidisciplinary
research group (2): (1) clinical deterioration caused by DCI and
(2) cerebral infarction.
Delayed cerebral ischemia is defined as “the occurrence of focal
neurological impairing (such as hemiparesis, aphasia, apraxia,
hemianopsia, or neglect) or a decrease of at least two points on
the Glasgow Coma Scale [either on the total score or one of its
individual components (eye, motor on either side, verbal)]. This
should last for at least 1 h, and is not apparent immediately after
aneurysm occlusion and cannot be attributed to other causes by
means of clinical assessments, cerebral CT or MRI scanning, and
appropriate laboratory studies. Nevertheless, the diagnosis of DCI
remains fairly subjective.
Cerebral infarction is defined as presence of cerebral infarction
on CT or MRI scan of the brain within 6 weeks after SAH, or on
the latest CT or MRI scan made before death within 6 weeks, or
proven at autopsy, not present on the CT or MR scan between 24
and 48 h after early aneurysm occlusion, and not attributable to
other causes (such as clipping or endovascular treatment). Hypo-
densities on CT imaging resulting from ventricular catheter or
intraparenchymal hematoma should not be regarded as cerebral
infarctions from DCI.
To remember, cerebral infarction correlates with the territory
of angiographic vasospasm in only 25–81% of SAH patients (1,
13). The term “vasospasm” was recommended to be reserved for
angiographic arterial narrowing. The occurrence of DCI should
be described separately from the results of angiography as not all
patients who experience DCI have angiographic vasospasm, and
not all patients with angiographic spasm have DCI.
REAL LIFE IN NEUROINTENSIVE CARE
Though knowing that the simple association of radiographic evi-
dence of vasospasm with clinical features of cerebral ischemia does
not take into account the different factors that may contribute
to DCI, most neurointensivist know a series of cases showing
an excellent correlation between an observed clinical deteriora-
tion and angiographic narrowing, with deficits easily reversible
with an increase of mean arterial blood pressure. In our view,
these concern mainly low WFNS grade patients, while in high-
WFNS grade patients, the large spectrum of difficult-to-diagnose
DCI/infarction is common. The diagnosis of DCI is limited and
the diagnosis of cerebral infarction possible only retrospectively
once an infarct is found radiographically (8). Obviously, interob-
server agreement rate is higher for cerebral infarction and easier
to evaluate in high-WFNS grade patients. Nevertheless, a sophis-
ticated evaluation is relevant also in this “difficult to evaluate and
treat” patient group, e.g., the clinical course is often complicated
by myocardial dysfunction, pneumonia, and acute respiratory
distress syndrome secondary to the aneurysm ruptures that fur-
ther complicate the “vasospasm” treatment and participates in
the worst outcome of high WFNS. Some of the factors proceed-
ing to infarction might be reversible if treated. The “infarction
diagnosis” reflects an under treatment of ongoing not detected
ischemia.
There are a series of worth-to-measure techniques, some of
them shortly summarized in the following, aimed to detect
“asymptomatic” ischemia in high-WFNS grade patients.
POSSIBLE CAUSES OF DCI
There are other potential mechanisms of primary and secondary
brain injury events related to DCI (14), some of them detectable
by neuromonitoring techniques.
(1) Intracranial pressure (ICP) and cerebral perfusion pres-
sure (CPP): ICP and CPP monitoring, obviously impor-
tant components of neurocritical care, are widely used in
comatose aSAH patients. ICP is preferentially measured as
external ventricular drainage (EVD), while in absence of
hydrocephalus/slit ventricles, an ICP probe may be used
instead, allowing continuous CPP monitoring. A high ICP
(>20 mmHg) is considered as an indirect but unspecific warn-
ing sign, is associated with energy failure, high secretion
of pro-inflammatory interleukins, and possibly aggravates
vasospasm. Optimal CPP is targeted individually depending
on several factors (ruptured aneurysm treated and presence
of DCI). Since CPP might not be available in all patients,
current guidelines (15) recommend (A) maintenance of euv-
olemia and normal circulating blood volume to prevent DCI
(Class I; Level of Evidence B, revised recommendation from
previous guidelines); (B) (new recommendation) induction
of hypertension for patients with DCI unless blood pressure is
elevated at baseline or cardiac status precludes it (Class I ; Level
of Evidence B); and (C) prophylactic hypervolemia before
the development of angiographic spasm is not recommended
(Class III ; Level of Evidence B).
(2) Among other pathomechanisms proposed, ischemia-producing
cortical spreading depolarizations (CSDs) are likely to be
involved in DCI development (16). CSDs are monitored by use
of subdural electrodes inserted after aneurysm clipping or an
EVD. CSD are self-propagating tissue depolarizations, associ-
ated with cessation of synaptic activity, surges of extracellular
potassium, opening of the blood–brain barrier with edema
formation, tissue hypoxia, and inversion to the normal CBF
response to neuroglial activity (11, 17). Recent clinical data
confirm that a complex cascade of interconnected molecu-
lar, metabolic, electrophysiological, and vascular disturbances
may lead to ischemia, homologous to animal models (18). The
discovery of SDs may lead to a better explanation of DCI in
patients with SAH. However, the definite role of SD and its
therapeutic implications in SAH are yet unclear (19). Results
from the ongoing multicenter Discharge-1 trial (Depolariza-
tions in ISCHaemia after subARachnoid haemorrhaGE-1) are
awaited.
(3) Disturbed cerebrovascular autoregulation in the first 5 days
after SAH significantly increases the odds of DCI occurrence
and was shown to have a better predictive value than classical
TCD monitoring protocols (20). Initial (first 48 h) preserved
cerebrovascular autoregulation in severe SAH grade patients is
a good predictor of survival. Optimal CPP (CPPopt) is defined
as the lowest CPP corresponding to the strongest cerebrovas-
cular autoregulation activity. It has been shown that CPPopt
increases during the vasospasm period for almost all SAH
patients but more significantly in the group of patients who
suffer vasospasm as assessed by TCDs (21).
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(4) Neurological wake-up test (interruption of sedation, IS-trial).
Clinical deteriorations, such as occurrence of focal neurolog-
ical impairing such as aphasia and hemiparesis are warning
signs for potentially DCI, which are difficult to evaluate in
high-grade SAH patients. The effect of interruption of seda-
tives and analgesics on neurologic assessment, hemodynamic
changes, brain metabolism, and brain tissue oxygen have
shown that (1) IS-trials were not attempted on one-third of
eligible days due to safety concerns, and that (2) one-third of
performed trials had to be stopped due to a critical increase
in ICP and impending brain tissue hypoxia. All IS-trials were
associated with cardiopulmonary stress, and detection of a
new neurological deficit that led to changes in management
occurred in only one trial (22). Nevertheless, cerebral metab-
olism and oxygenation was not affected in a recent trial
(traumatic brain injury, TBI, patients) (23). This suggests that
IS-trials are safe in the majority of patients but that the test
should be individualized and avoided in patients reacting with
markedly increased ICP and/or decreased CPP (23). In con-
trast to TBI, the dynamics for detection of a new deficit in
aSAH patients are more variable and potentially treatable, sug-
gesting an important role for IS-trials in aSAH patients. Lack-
ing detailed guidelines, the limitation for this maneuver, in
our view, is the stability of ICP and the targeted CPP avoiding
arterial hypotension/cerebral hypoperfusion and obviously,
ideally under control of further neuromonitoring parameters.
(5) Monitoring of cerebral oxygenation. The regionally moni-
toring brain tissue partial pressure of oxygen sensor and
the globally measuring jugular bulb oximetry allowing fur-
ther analysis of arterial-venous differences of energy-related
factors are commonly used techniques for detection of
cerebral hypoxia/ischemia. A decrease of brain tissue PO2
(<15−10 mmHg) and/or jugular bulb oxygenation (<70%)
are warning signs and sensibilize the neurointensivist for
occurring processes leading to progressive, clinically not
detectable ischemia, infarction, and unfavorable outcome in
this high-risk SAH population.
(6) Cerebral metabolism. Lacking clinical features to diagnose a
neurological deterioration in high-WFNS grade patients, cere-
bral microdialysis provides information on the metabolic state
of the injured brain and allows for determination of a vari-
ety of markers of ischemia and immunocompetence in the
cerebral extracellular fluid (ECF). This is of relevance since
both the blood–brain and blood–CSF barriers may be vari-
ably disrupted following aSAH, rendering blood and CSF
levels of such markers less reliable. Probes are implanted
directly into the region of interest, typically after aneurysm
clipping. Profound changes in extracellular glucose, lactate,
glutamate, and glycerol in patients with signs of acute or
delayed ischemia have been shown (24, 25). Accepted thresh-
olds to indicate metabolic crisis/ischemia are in the first line
defined for the lactate–pyruvate ratio >25–40 and glucose
<0.5 mM and in second line for glutamate>40 mM; however,
individual trends are very important for careful interpreta-
tion. The method was especially valuable in patients with
acute focal deficits on admission (AFND) due to concomitant
intracerebral hemorrhage or edema post aSAH (26, 27). As it
is a time- and cost-intense method, only few centers continued
monitoring, mainly focusing on possible biomarkers predict-
ing DCI, early brain injury (28), and related inflammatory
processes (29).
EARLY BRAIN INJURY, DCI, AND IMMUNE SYSTEM
The finding that prevention of delayed vasospasm does not
improve outcome in aSAH patients has brought into focus the
influence of early brain injury on outcome of aSAH. A substan-
tial amount of evidence indicates that brain injury begins at the
aneurysm rupture, evolves with time, and plays an important role
in patients’ outcome. It is postulated that intraparenchymal acti-
vation of the immune system after aSAH contributes to secondary
brain injury. Intraparenchymal inflammation has been linked to
progression of aSAH-induced secondary brain damage (30, 31).
More specifically, leukocyte–endothelial cell interactions appear
to play a critical role in vasospasm. It is hypothesized that the
development of DCI is promoted by these inflammatory processes
leading to a decreased immunocompetence and secondarily to
infectious complications (32). Putative promising markers to indi-
cate immunosuppression are low HLADR and high interleukin-6
levels (thresholds depending on laboratory).
Another point is the entity of patients “at high risk” presenting
with acute focal neurological deficits (AFND) on admission (26).
Most, but not all of them, are high-WFNS grade patients; however,
presenting early brain damages, such as an intracerebral hemor-
rhage, edema, and high ICP not related to hydrocephalus. These
patients show the most severe immunodepression and highest
infection rate of the aSAH population (28, 32).
SUMMARY
In conclusion, the use of clear definitions to classify: (1) occur-
ring deficits such as AFND and DCI, (2) pathomechanisms such
as CSD, cerebral hypoxia, disturbed cerebral autoregulation, cere-
bral metabolism, and inflammation alterations, and (3) resulting
lesion using precise time windows and assessment techniques will
allow to better share experiences on the disease and improve
its understanding. Advanced neuromonitoring techniques may
offer the neurointensivists complementary tools to better perceive
the pathological condition and engage appropriate treatments
that would otherwise lead to progressive, clinically not detectable
ischemia, infarction, and unfavorable outcome in high-risk SAH
population.
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